Editorial: MYC as a disease target beyond cancer

This editorial argues that the transcription factor MYC represents a viable therapeutic target for diseases beyond its well-established role in oncology. The author highlights emerging evidence suggesting that dysregulated MYC activity contributes to various non-cancerous pathological conditions, thereby expanding the scope of potential pharmacological interventions. While acknowledging the historical focus on cancer, the piece advocates for broader investigation into MYC modulation across different disease etiologies. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works